Molecular- and organelle-based predictive paradigm underlying recovery by left ventricular assist device support.
David A Liem,Ali Nsair,Shaun P Setty,Martin Cadeiras,Ding Wang,Robb Maclellan,Chris Lotz,Amanda J Lin,Jason Tabaraki,Hua Li,Junbo Ge,Jacob Odeberg,Fredrik Ponten,Erik Larson,Jan Mulder,Emma Lundberg,James N Weiss,Mathias Uhlen,Peipei Ping,Mario C Deng
DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.113.000250
2014-01-01
Abstract:HomeCirculation: Heart FailureVol. 7, No. 2Molecular- and Organelle-Based Predictive Paradigm Underlying Recovery by Left Ventricular Assist Device Support Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessResearch ArticlePDF/EPUBMolecular- and Organelle-Based Predictive Paradigm Underlying Recovery by Left Ventricular Assist Device Support David A. Liem, MD, PhD, Ali Nsair, MD, Shaun P. Setty, MD, Martin Cadeiras, MD, Ding Wang, PhD, Robb Maclellan, MD, Chris Lotz, MD, Amanda J. Lin, Jason Tabaraki, Hua Li, MD, Junbo Ge, MD, PhD, Jacob Odeberg, MD, PhD, Fredrik Ponten, MD, Erik Larson, MD, PhD, Jan Mulder, PhD, Emma Lundberg, PhD, James N. Weiss, MD, Mathias Uhlen, PhD, Peipei Ping, PhD and Mario C. Deng, MD David A. LiemDavid A. Liem From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). *Drs Liem, Nsair, and Setty contributed equally to this work. Search for more papers by this author , Ali NsairAli Nsair From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). *Drs Liem, Nsair, and Setty contributed equally to this work. Search for more papers by this author , Shaun P. SettyShaun P. Setty From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). *Drs Liem, Nsair, and Setty contributed equally to this work. Search for more papers by this author , Martin CadeirasMartin Cadeiras From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). Search for more papers by this author , Ding WangDing Wang From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). Search for more papers by this author , Robb MaclellanRobb Maclellan From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). Search for more papers by this author , Chris LotzChris Lotz From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). Search for more papers by this author , Amanda J. LinAmanda J. Lin From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). Search for more papers by this author , Jason TabarakiJason Tabaraki From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). Search for more papers by this author , Hua LiHua Li From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). Search for more papers by this author , Junbo GeJunbo Ge From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). Search for more papers by this author , Jacob OdebergJacob Odeberg From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). Search for more papers by this author , Fredrik PontenFredrik Ponten From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). Search for more papers by this author , Erik LarsonErik Larson From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). Search for more papers by this author , Jan MulderJan Mulder From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). Search for more papers by this author , Emma LundbergEmma Lundberg From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). Search for more papers by this author , James N. WeissJames N. Weiss From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). Search for more papers by this author , Mathias UhlenMathias Uhlen From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). Search for more papers by this author , Peipei PingPeipei Ping From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). Search for more papers by this author and Mario C. DengMario C. Deng From the Departments of Physiology (D.A.L., A.N., D.W., C.L., A.J.L., J.T., J.N.W., P.P.) and Medicine, Division of Cardiology (D.A.L., A.N., M.C., R.M., J.N.W., P.P., M.C.D.), David Geffen School of Medicine at University of California, Los Angeles; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden (J.O., F.P., E. Larson, J.M., E. Lundberg, M.U.); Department of Pediatric and Adult Congenital Cardiac Surgery, Miller Children’s Hospital and Long Beach Memorial Hospital, CA (S.P.S.); and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai, China (H.L., J.G.). Search for more papers by this author Originally published1 Mar 2014https://doi.org/10.1161/CIRCHEARTFAILURE.113.000250Circulation: Heart Failure. 2014;7:359–366History of Mechanical Circulatory Support DevicesAdvanced heart failure (HF) is a major cause of morbidity and mortality in the United States, and heart transplantation remains as the gold standard therapy. Because of scarcity of donor organs, the application of mechanical circulatory support devices has become a crucial approach in HF therapy as a bridge to transplantation. Therefore, mechanical circulatory support devices have existed both conceptually and experimentally for >40 years, along which an exponential evolution of mechanical circulatory support device technology has occurred. To mimic human physiology, the first generation of left ventricular assist devices (LVADs) were pulsatile volume displacement pumps (HeartMate XVE LVAS, Thoratec PVAD, and Novacor, etc). Insights demonstrating the inessentiality of the pulsatile nature of LVADs for survival from a physiological standpoint propelled the design of second-generation continuous flow devices (HeartMate II [Thoratec Inc], the Micromed DeBakey VAD, Berlin Heart Incor [Berlin Heart AG], and the Jarvik 2000 [Jarvik Heart Inc]), which emerged with superior safety and durability. Consequently, the HeartMate II was approved for bridge to transplantation and destination therapy in the United States.1 Recent reports2,3 have demonstrated a 2-year survival rate of 87% in destination therapy patients under intense surveillance, comparable with open heart transplantation survival statistics. In parallel, these promising outcomes of LVADs in HF therapy have spawned the translational research field of LV reverse remodeling, which has already shown great promise for elucidating underlying molecular and cellular mechanisms.Clinical Insights Into Bridge to RecoveryHF is a highly complex clinical syndrome marked by a multitude of derangements, both in adult and pediatric populations.4 The clinical phenotype of HF begins with an injury or supranormal stressor on the heart and, through prolonged dyshomeostasis, eventuates in cellular and organ failure. The compensatory adaptive mechanisms including neurohormonal activation (eg, the adrenergic system along with aldosterone, renin, and angiotensin) may initially maintain cardiac output, but the inability to sustain this eventually results in HF together with the release of proinflammatory cytokines. The response to neurohormonal activation, direct mechanical stretch, and LV volume overload results in progressive maladaptive remodeling (Figure 1). These derangements are potentially reversed during LVAD mechanical unloading.5–7Download figureDownload PowerPointFigure 1. Pathophysiology of heart failure. Compensatory mechanisms to maintain cardiac output eventually result in negative remodeling of the ventricles. NYHA indicates New York Heart Association.The current gold standard therapy for HF is open heart transplantation, yet it carries a 50% 10-year survival along with all complications related to long-term immunosuppression and increased medical costs. With the evolution of LVAD technology and reliability, there has been anecdotal evidence of sufficient LV recovery by LVAD support to a point allowing device removal (ie, bridge to recovery [BTR]).8 The Harefield group was the first to study a homogenous population of patients with HF, in which they applied a defined pharmacological protocol along with LVAD unloading to induce recovery. This involved high-intensity neurohormonal blockade followed by induction of physiological hypertrophy with a high-dose clenbuterol, a direct β-agonist, to optimize LV recovery. The procedure resulted in 63.2% of patients successfully recovering after LVAD explantation.9Reliable and robust predictive parameters and patient selection criteria for successful BTR have not yet been established. Patients with nonischemic cardiomyopathy (NICM) have been targeted in studies10,11 as the group most likely to undergo successful BTR. However, this NICM population itself has heterogeneous underlying causes, such as viral myocarditis, postpartum cardiomyopathy, direct toxin or radiation exposure, and congenital cardiomyopathies. Pre-existing clinical determinants, such as older age, larger LV diameters before LVAD implantation, higher degree of myocardial fibrosis, and a prolonged duration of HF >6 months, have been predictive of decreased success of recovery in patients with NICM and higher risk of developing HF after LVAD explantation.12 In the HeartMate II bridge-to-transplant and destination therapy trials enrolling 1108 patients with NICM, HF of <1 year and age of ≤45 years were predictors of successful BTR and 2-year transplant-free survival.13Furthermore, echocardiographic measurements such as ejection fraction (EF), LV end-diastolic dimension, right ventricular size and wall thickness, and degree of mitral and aortic insufficiency have been used as critical parameters to predict myocardial recovery after explantation. Dandel et al12 found that EF >50% in patients with NICM before LVAD explantation correlated with a 91.7% chance of cardiac stability lasting ≥5 years after LVAD removal. In contrast, EF <50% correlated with a 1.5-fold increase in the recurrence of HF at 5 years.12 The positive predictive value of EF could be enhanced if additional parameters such as pre-explantation LV size and geometry, stability of unloading-induced cardiac improvement before LVAD removal, and HF duration before LVAD implantation were also considered. The recovery rate of LVEF after LVAD implantation has been associated with prolonged HF recovery after LVAD explantation as well.14A growing area of interest is the determination of cardiac reserves and functional capacity beyond the scope of echocardiography parameters to facilitate further prognostication of patients’ recoverability after LVAD implantation.15,16 MVO2 max and hemodynamic data, such as cardiac output, pulmonary arterial pressures, and LV end-diastolic pressure at low-level flows of HeartMate II have been studied. Exercise capacity was assessed through 6-minute walk tests at minimal flow rates to determine inotropic reserve. In the second Harefield study,10 several patients underwent explantation because of other complications, which necessitated LVAD removal before achieving certain echo parameters. These patients performed remarkably well; however, detailed molecular assessments of the cardiac recovery in these successful cases of BTR were not performed.11,12Morphological, Molecular, and Cellular Insights of Reverse Remodeling After LVAD SupportMorphological and Molecular InsightsDuring the past 2 decades, molecular and cellular recovery after LVAD mechanical unloading (Figure 2) has been extensively investigated in an effort to understand the pathophysiology and critical pathways for potential therapeutic applications (Table).5–7,17 The current consensus is that morphological, cellular, and molecular reversal after LVAD implantation precedes clinical recovery. However, these features alone have not been able to predict clinical recovery reliably.7 With regard to morphological changes, several early histological studies described a conclusive decrease in cell volume and morphological restructuring to a prediseased state.5,6,17 Accordingly, there are reports demonstrating the normalization of cardiac sarcomeric proteins, including vinculin, desmin, tubulin, tropomyosin, titin, actinin, and α-spectrin.5,6,17 LVAD support also led to enhancements in cardiomyocyte force in conjunction with accelerated contraction and relaxation times.6 Nevertheless, whether interstitial connective tissue remodeling can be reversed after LVAD support remains controversial.5,6Table. Summary of Molecular/Cellular Constituents in Reverse Ventricular Remodeling After LVAD ImplantationCardiac FeatureCellular/Molecular ConstituentEffect of LVAD TherapyRelevanceExtracellular matrix, cytoskeleton, and sarcomere biogenesisCollagen/fibrosisDecreased or increased depositExtracellular matrix remodeling is key in HF and myocardial recovery, contradicting reportsMetalloproteinases/matrix metalloproteinasesAlterationsEnzymes involved in breakdown of collagen in HF and reverse remodelingDystrophinDisruption is reversedRole of reversal is still unclearMyosin heavy chainIncreasedImportant for functional contractile recoveryTroponin T, troponin C, actin, smooth muscle α-actinIncreasedImportant for functional contractile recoveryVinculin, desmin, tubulinAbundant changes after PTMIndicates a restored contractile apparatusTropomyosin, titinRecoveredOnly partially recovered despite improvement of the myocardial size, important during cardiac contractionActinin, α-spectrinIncreasedIndicates restored shape and structure of cardiomyocytesInflammatory responseTNF-α, IL-8, complement C3a, glycoprotein 130DecreasedBoth in circulating and LV tissue, indicates a significant role of inflammation in HF progressionIL-6IncreasedIL-6 increased in HF and contributes to myocardial injuryNeurohormonal releaseEpinephrine and norepinephrineDecreasedSignificant in myocardial recovery attributable to deleterious effect on myocardium if chronically elevated as in HFRenin, AT-II, aldosterone, arginine vasopressinDecreasedSignificant in myocardial recovery attributable to deleterious effect on myocardium if chronically elevated as in HFANP, BNPDecreased in both circulating and cardiac tissueProminent HF biomarker, both act through guanyl cyclase-ACalcium handlingSarcolemmal calcium flux through sarcoplasmic channelIncreased calcium pumping functionRestored after LVAD implantation but requires optimal timing of LV unloadingSarcoplasmic reticulum calcium contentIncreasedLeading to shorter action potential durationsSERCA2aIncreased gene expression in LV (not in RV)Protein abundance of SERCA is unclear (different studies show discrepancy)Na+/Ca2+ exchangerIncreased expression and functionLeads to better contractility and inotropyPhospholambanUnchangedRatio of SERCA/phospholamban may improve, which is important in functional recovery and contractilityL-type calcium channelFlux improved after PTMIndicates improved contractilityRyanodine receptorFunction in LV and RV improved after PTMIndicates improved contractilityβ-Adrenergic signalingβ-Receptor density and locationReversal of receptor downregulation and improved densityCorrelated to reverse PI3K-γ activation and an increase of adenylyl cyclaseβ-Receptors locationNormalized in plasma membranesDepletion of receptors in endosomesAdenylyl cyclaseIncreased after LVAD implantationSignificant component in β-adrenergic signal transductionMetabolismCreatine kinaseIncreased back to normal levelsIndicates reversed cell damageCardiolipinNormalized composition in ischemic cardiomyopathyIndicates a significant role in ischemic heart diseaseSignal transductionPI3K/Akt/GSK-3β pathway, IGF, FGF, RTKs, Her2/neuUpregulated or no changes, Her2/neu upregulatedPotential targets for pharmacotherapy, IGF is correlated to stem cell recruitmentMAP/Erk/JNK/P38 pathwayErk downregulated, Erk no changePotential targets for pharmacotherapyApoptosisB-cell lymphoma 2NormalizedDiscrepancy whether apoptosis is increased or decreasedMyocyte nucleusCell cyclePossible reactivationMay allow cardiac regenerationCardiomyocyte DNA content and number of polyploid cellsDecline after LVAD implantationMay allow cardiac regenerationNumber of diploid and binucleated myocytesIncreased after LVAD implantationMay allow cardiac regenerationGene expressionMany altered genes during HFOnly small percentage of transcripts show reversalReverse remodeling may occur without normalization of abnormal gene expressionMicroRNA expressionMany microRNAs in HF are up- or downregulatedMany microRNAs show normalizationMay be more sensitive to study reverse remodeling than genesAkt indicates protein kinase B; ANP, atrial natriuretic peptide; AT, angiotensin; BNP, brain natriuretic peptide; Erk, extracellular signal-regulated kinases; FGF, fibroblast growth factor; GSK-3β, glycogen synthase kinase-3β; Her2/neu, human epidermal growth factor receptor 2; HF, heart failure; IGF, insulin-like growth factor; Il, interleukin; JNK, c-Jun N-terminal kinase; LVAD, left ventricular assist device; MAP, mitogen-activated protein; PI3K, phosphoinositide 3-kinase; PTM, post translational modification; RTK, receptor tyrosine kinase; RV, right ventricle; SERCA2a, sarco-endoplasmic reticular Ca2+ ATPase subtype 2a; and TNF, tumor necrosis factor.Download figureDownload PowerPointFigure 2. Main levels of reverse remodeling after left ventricular assist device (LVAD) implantation. Functional, organellar, and molecular recovery in reversed ventricular remodeling. RCI indicates respiratory control index; and SR, sarcoplasmic reticulum.As a governing determinant of cardiac function, calcium (Ca2+) handling of the cell is disturbed during HF, which may contribute to the decreased contractility. In this regard, there seems to be increased gene expression of the sarcolemmal Na+Ca2+ exchanger and sarco-endoplasmic reticular Ca2+ ATPase subtype 2a after LVAD implantation, but corresponding protein expression remains unclear. Furthermore, levels of the Ca2+ regulatory protein phospholamban seems to be unchanged after LVAD implantation, whereas L-type Ca2+ channel function and ryanodine receptor function are improved through post-translational modifications after LVAD implantation.5,6Cardiac function is also orchestrated by the neurohormonal system, and there is clear evidence that increased levels of neurohormones during HF (such as epinephrine, norepinephrine, renin, angiotensin II, aldosterone, and arginine vasopressin) are decreased with successful LVAD support.5,6,17 Other key hormonal players in maintaining arterial blood pressure and volume homeostasis are cardiac atrial natriuretic peptide and B-type natriuretic peptide.5,6,17 Both atrial natriuretic peptide and B-type natriuretic peptide are important HF biomarkers that are released by the atrium and LV, respectively, on pressure overload. Because LVAD therapy immediately relieves the burden on the overloaded heart, both atrial natriuretic peptide and B-type natriuretic peptide levels show a downward trend. In addition, β-adrenergic receptor density and response to stimulation can be restored after LVAD support, most likely through alterations in intracellular rather than hemodynamic factors,5–7 and also reversed phosphoinositide 3-kinase-γ activation and alterations in adenylyl cyclase.Certain aspects of mitochondrial structure and function have been investigated. Metabolism is disrupted during HF, yet studies on the effects of LVAD support on metabolic pathways are limited. Decreased creatine kinase activity during HF is restored after LVAD support, indicating improved energy production. Moreover, the composition of cardiolipin, an integral component of the mitochondrial inner membrane that facilitates the function of numerous energetic enzymes, is normalized, after LVAD support in ischemic cardiomyopathy, but not in dilated cardiomyopathy.5,6,17The inflammatory response characteristic of HF progre